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Abstract
Background
Melanopsin-expressing retinal ganglion cells (mRGCs), intrinsically photosensitive RGCs,
mediate the light-based pupil response and the light entrainment of the body’s circadian
rhythms through their connection to the pretectal nucleus and hypothalamus, respectively.
Increased awareness of circadian rhythm dysfunction in neurological conditions including
Alzheimer’s disease (AD), has led to a wave of research focusing on the role of mRGCs in
these diseases. Postmortem retinal analyses in AD patients demonstrated a significant loss
of mRGCs, and in vivo measurements of mRGC function with chromatic pupillometry may
be a potential biomarker for early diagnosis and progression of AD.
Methods
We performed a prospective case-control study in 20 cognitively healthy study participants:
10 individuals with pre-symptomatic AD pathology (pre-AD), identified by the presence of
abnormal levels of amyloid β42 and total Tau proteins in the cerebrospinal fluid, and 10 age-
matched controls with normal CSF amyloid β42 and Tau levels. To evaluate mRGC function,
we used a standardized protocol of chromatic pupillometry on a Ganzfeld system using red
(640 nm) and blue (450 nm) light stimuli and measured the pupillary light response (PLR).
Non-invasive wrist actigraphy and standardized sleep questionnaires were also completed
to evaluate rest-activity circadian rhythm.
Results
Our results did not demonstrate a significant difference of the PLR between pre-AD and con-
trols but showed a variability of the PLR in the pre-AD group compared with controls on
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chromatic pupillometry. Wrist actigraphy showed variable sleep-wake patterns and irregular
circadian rhythms in the pre-AD group compared with controls.
Conclusions
The variability seen in measurements of mRGC function and sleep-wake cycle in the pre-
AD group suggests that mRGC dysfunction occurs in the pre-symptomatic AD stages, pre-
ceding cognitive decline. Future longitudinal studies following progression of these partici-
pants can help in elucidating the relationship between mRGCs and circadian rhythm
dysfunction in AD.
Introduction
Alzheimer’s disease (AD) is the most frequent type of dementia, characterized by abnormal
accumulation of misfolded amyloid-ß (Aß) protein and hyperphosphorylated-Tau in the
brain, in the form of amyloid plaques and neurofibrillary tangles respectively. Diagnosis of def-
inite AD requires post mortem brain analysis, and thus is difficult to predict especially prior to
clinical manifestations [1–3]. In vivo quantification of Aß and Tau proteins and their ratio in
the cerebrospinal fluid (CSF), coupled with neuroimaging and neuropsychological studies, is
often used to evaluate the likelihood of probable or possible AD diagnosis [4]. CSF biomarkers
can also be helpful to identify asymptomatic patients at risk to develop AD in the future. The
search for additional in vivo markers to improve early diagnosis of AD or measure progression
is expanding and the eye represents a promising field of research [5].
Primary symptoms of AD include cognitive impairment and memory loss. In addition,
visual complaints are reported by AD patients even in early stages of disease, usually reflecting
the progressive neurodegeneration along the parietal-occipital cortex and the posterior visual
pathways [5, 6]. Nevertheless, a more anterior involvement, of both the retina and optic nerve,
is nowadays well established in AD and may precede brain pathology [4–6]. In human post-
mortem specimens and animal models, histological studies demonstrated the characteristic
Aß deposits and Tauopathy in the inner retina, which are associated with degeneration of reti-
nal ganglion cells (RGCs) and macular and optic nerve thinning with predominant loss of
larger fibers in the superior quadrant [7–9].
Many optical coherence tomography (OCT) studies confirmed in vivo the reduction of reti-
nal nerve fiber layer (RNFL) thickness in AD patients compared to controls, with evidence of
intermediate values in patients with mild cognitive impairment (MCI) [10, 11]. RNFL thin-
ning, consistent with histological evidence, was seen in the superior and inferior quadrants
with a relative sparing of the temporal quadrant [7]. This pattern differs from studies in
patients with mitochondrial optic neuropathies and other neurodegenerative diseases, like
Parkinson’s and Huntington’s Diseases, where there is a preferential involvement of the tem-
poral quadrants due to loss of the smaller RCGs [7, 12].
Moreover, La Morgia and coauthors demonstrated a significant loss of intrinsically photo-
sensitive RGC containing melanopsin (mRGCs) in AD compared to controls and that these
cells are selectively affected by the amyloid pathology in post-mortem retinal tissues. MRGCs
are part of a non-visual pathway responsible for the PLR and the light entrainment of circadian
rhythms with multiple connections in the brain including the suprachiasmatic nucleus of the
hypothalamus [13, 14]. Hannibal and coauthors demonstrated in humans the projections of
mRGCs to the the suprachiasmatic nucleus, the site of circadian regulation [15]. Thus, mRGC
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degeneration may explain the dysregulation of sleep-wake cycle characteristically observed in
aging and Alzheimer’s disease. This is supported by several actigraphy studies showing differ-
ent profiles of circadian dysfunction with decreased sleep latency and overall sleep time com-
pared to controls [7–9, 16–18].
Interest on the in vivo evaluation of mRGC function as a potential biomarker for different
pathological conditions is growing. Melanopsin is a photopigment contained in mRGCs that
selectively reacts to short-wavelength blue light (459–483 nm) [8, 9, 19, 20]. The immediate
and apparent reaction to mRCGs depolarization in response to light is a pupillary constriction
that can be assessed by chromatic pupillometry [8, 9, 19, 20]. Protocols using blue and red
light flashes of increasing luminance, after dark or light adaptation, showed that mRGC-medi-
ated pupillary response differs from cone or rod-driven responses [21, 22].The mRGC-medi-
ated pupillary light response (PLR) shows a sustained response to colored stimuli, with pupil
size returning slowly to baseline pupil amplitudes [21].
Chromatic pupillometry has been used to assess mRGC function in various conditions.
Studies in Leber’s hereditary optic neuropathy (LHON) demonstrated a selective preservation
of mRGCs with a normal PLR [20]. While in glaucoma and Parkinson’s disease, PLR ampli-
tude was reduced compared with controls [9, 19, 23]. A few studies have used pupillometry to
study mRGC function in AD [8, 24]. Pupillometry may also be helpful to measure early
changes in mRGC function in older participants without clinical symptoms but with clinically
probable AD differentiated by CSF or imaging biomarkers. However, the results have been
variable and the utility of pupillometry in AD and pre-symptomatic AD remains inconclusive
[24–28].
The purpose of this study was to specifically evaluate mRGC function with chromatic pupil-
lometry in pre-symptomatic AD. Prolonged wrist actigraphy recording and sleep question-
naires were also completed to detect early changes in circadian sleep-wake cycle.
Materials and methods
Study participants
This was a prospective case-control study conducted at the Doheny Eye Center, Division of
Neuro-ophthalmology, in Pasadena, California and the Huntington Medical Research Insti-
tutes. The study was approved by the Institutional Review Board of the Huntington Hospital,
Pasadena, California and the University of California, Los Angeles (IRB#17–001645), as per
their policies. The study was in compliance with the Declaration of Helsinki. Study partici-
pants over 60 years of age were recruited prospectively for this Brain Aging research study
(Protocol 37937) from the local San Gabriel Valley area as described [4]. Only participants
who were determined to have no cognitive impairment by Uniform Data Set-3 assessments as
described in the National Alzheimer’s Coordinating Center and consensus clinical conferenc-
ing, were included [29]. All participants provided written, informed consent of the study after
the purpose and methods of the study were thoroughly explained. We classified these cogni-
tively healthy individuals into two groups depending on the result of CSF analysis for Alzhei-
mer’s disease (AD) biomarkers: those with a pathological value of Aβ42 /Tau ratio were
considered as pre-symptomatic AD (pre-AD) [4], or those with a normal Aβ42 /Tau ratio as a
control group. This cutoff for the CSF Aß42/Tau ratio had been previously found to correctly
classify >85% of individuals with clinically probable AD [4].
All participants completed thorough ophthalmic and cognitive evaluation and exhibited no
significant differences in age, gender, education, medications, vascular risk factors, and mag-
netic resonance imaging features of small vessel disease. Exclusion criteria included were best
corrected visual acuity less than 20/50, pre-existing macular pathologies, and neurological,
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psychiatric, or ocular diseases. Participants who were diagnosed by a physician with sleep
apnea or used continuous positive airway pressure machines were excluded from wrist actigra-
phy analyses. Participants in the control group with significant sleep disturbances as evaluated
by sleep questionnaires were also excluded in analyses of wrist actigraphy and subjective sleep.
Chromatic pupillometry evaluation
MRGC cell-mediated PLR was assessed using previously established chromatic pupillometry
protocols [20, 21]. We focused on measuring the sustained response to the intense blue stimuli
in the dark to target the melanopsin condition [21]. The dominant eye was tested, and the con-
tralateral eye was patched for monocular testing. Participants sat with their eyes open in a dark
room for 10 minutes to naturally dilate their eyes prior to chromatic pupillometry testing. Col-
ored light stimuli were presented for one second each using a Ganzfeld ColorDome full-field
stimulator (Diagnosys, UK, Ltd) with an integrated pupillometer to record the pupil response.
We referenced the protocol described by Park and coauthors, which describes isolating rod,
cone, and melanopsin contributions to the PLR using different wavelengths, intensities, and
adaptations [21]. In this study, we focused on the melanopsin condition of their protocol using
intense photopically matched red and blue stimuli in the dark to specifically assess the contri-
bution of mRGCs to the PLR [21]. We presented a flash stimulus of intense red light (620 nm)
for 1 second at a luminance of 250 candels per square meter (2.3 log cd/m2). We then repeated
the recording with the photopically matched blue stimulus (450 nm) for 1 second. The inter-
stimulus interval (ISI) was 20 seconds for the red stimulus and 40 seconds for the blue stimu-
lus. All recordings were completed in the same order with the red stimulus followed by the
blue stimulus. PLR recordings were repeated three times for each colored stimulus and the
recordings were averaged. Participants were instructed to try their best to keep their eyes open
during the duration of the light stimuli as well as for 10 seconds following the stimuli. Partici-
pants who blinked frequently during the recordings were given another opportunity to repeat
the measurements.
Each trial of PLR for all participants were inspected visually by a masked administrator to
confirm for data quality and additional artifacts. The PLRs for each participant were normal-
ized by the baseline pupil size, defined as the mean pupil size during the 1 second before stimu-
lus onset. Normalized pupil size was calculated by absolute pupil size/baseine pupil size. The
peak amplitude or peak normalized pupil size was defined as the pupil size at the point of
greatest constriction or the minimium pupil size. Sustained response was defined as the nor-
malized median pupil size in the time window between 6 to 8 seconds from flash onset. We
compared the pupil size at baseline, peak amplitude, and sustained response between the pre-
AD and controls for the PLR following both colored stimuli and compared the results between
the two groups.
Wrist actigraphy and sleep questionnaires
Participants were instructed to wear a non-invasive, lightweight, waterproof wrist watch with
an embedded actigraphy device (ActigraphMotionwatch8, Camntech, Ltd) on either wrist.
Because there were only two actigraphy devices available for all participants and participants
took each device home, only a subset of participants were able to complete both the pupillome-
try and actigraphy. Participants were instructed to wear the wrist actigraphy device for at least
5 consecutive days and to keep a sleep diary that recorded their bed and rise time, daytime
naps, or any time they removed the watch for any reason. Participants were advised on remov-
ing the watch during water activities such as showering or swimming, which might damage
the device. Patients with less than 5 consecutive days of recorded data were excluded.
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Actigraphy analyses were completed using TheMotionware software (Camtech, Ltd). We
compared non-parametric measures of circadian stability including intra-daily variability (IV,
degree of fragmentation of activity-rest periods, range: 0–2), interdaily stability (IS, degree of
regularity, range 0–1) and relative amplitude (RA, (M10 –L5)/ (M10 + L5), range 0–1), most
10 average (M10, activity during most ten active hours), and least 5 average (L5, activity for
least five active hours) [30]. Intra-daily variability (range 0–2) measured the frequency of tran-
sitions between rest and activity. Interdaily stability (range of 0–1) measured the strength of
rhythm and degree of regularity in the activity-rest pattern. Relative amplitude measured the
normalized difference between the most active 10 hour period (M10) and the least active 5
hour period (L5). Total sleep time was defined as the minutes of rest activity during a night
period. Sleep efficiency was calculated by the percentage of total sleep time divided by time in
bed. All measurements were averaged during the nights of sleep for each participant and com-
pared between the pre-AD and control groups.
All participants also completed three standardized self-administered questionnaires
(Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI) and Berlin Question-
naire to evaluate the possible occurrence of sleep disturbances. Participants with pathologic
scores on these questionnaires were differentiated as those who scored above 10 on the ESS,
above 5 for PSQI, and high risk on the Berlin questionnaire.
Statistical analyses
Statistical analysis was completed using commercial spreadsheet software (Microsoft Excel;
Microsoft Corporation, Redmond, WA). All pupillometry recordings were evaluated to ensure
that the average response of the three recordings for each colored stimuli was appropriate.
Pupillometry data were analyzed offline using Prism software (San Diego, CA) paralleling the
protocol used by several different studies [28, 31]. Recordings with multiple eye blinks that
contaminated the PLR pattern or curvature were rejected.
After determining variables were not normally distributed by the Kolmogorov-Smirnov
test, a non-parametric Mann Whitney U test was used to compare pupillometry and actigra-
phy measurements between controls and pre-AD participants. A two-tailed Spearman correla-
tion was performed to measure the relationship between Aβ42/Tau ratios with the chromatic
pupillometry, wrist actigraphy, and sleep questionnaire measurements for both controls and
pre-AD participants.
Results
Demographics
We recruited a total of 20 subjects, 10 controls (mean age: 72.7 ± 7.9 years, 70% female) and 10
pre-AD (mean age: 75.7 ± 6.3 years, 90% female). Demographic data of the participants are
seen in Table 1. There was no significant difference in age, BMI, or visual acuity between con-
trols and pre-AD groups. The values of Aβ42 /Tau ratio in the CSF were significantly decreased
in the pre-AD (1.5 ± 0.4) compared with controls (4.3 ± 1.2; p = 0.0007). There was no signifi-
cant correlation between Aβ42 /Tau ratio and age for all participants (controls r: 0.22, p = 0.54;
pre-AD: r: 0.25, p = 0.52, nonparametric Spearman correlation).
Pupillary light response with chromatic pupillometry
All 20 participants (10 pre-AD individuals and 10 age-matched controls) completed chromatic
pupillometry recordings for both the red and blue stimuli. One control participant had a
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recording that did not resemble a PLR for the blue stimulus, and this recording was excluded
from analysis.
All pre-AD participants and controls showed measurable PLRs with the intense red and
blue stimuli (Fig 1). The blue light evoked a much stronger PLR with a longer sustained
response compared to the red stimulus when matched for photopic luminance. The PLRs for
the intense blue stimulus showed a slower return to baseline pupil size following light offset
(blue lines in Fig 1) while the PLRs to the intense red stimulus showed a quick return to base-
line pupil size (red lines in Fig 1). On average, the PLRs for both the red and blue stimuli were
similar between the pre-AD and control group (Fig 1, solid red and blue lines). For the red
stimulus, individual pre-AD PLRs (Fig 1A, dashed red lines) were similar to control PLRs (Fig
1B, dashed blue lines). However for the blue stimulus, there was PLR variability in the pre-AD
group (Fig 1C, dashed blue lines) that was not seen in controls (Fig 1D, dashed blue lines). In
the control group, all but one participant showed PLRs to the blue stimulus that were similar
to each other (Fig 1D).
Quantitative measurements of PLR, including the baseline pupil size, normalized peak
pupil size and sustained response, were not significantly different in pre-AD participants com-
pared with controls for both the intense red and blue stimuli (Fig 2, Table 2). The average base-
line pupil size was smaller in the pre-AD group compared to controls, although this was not
statistically significant (Table 2). The difference between PLRs to the two colored stimuli were
analyzed but neither peak nor sustained response showed a statistically significant difference
between the pre-AD and control group.
Aβ42 /Tau ratios were not significantly correlated in controls with the peak pupil size (red,
r: 0.18, p = 0.63; blue: r: -0.43, p = 0.25) and sustained response (red, r: 0.18, p = 0.63; blue: r:
-0.05, p = 0.91). There was no relationship for the pre-AD group as well, for the peak pupil size
(red, r: -0.28, p = 0.42; blue: r: -0.30, p = 0.41) and sustained response (red, r: 0.22, p = 0.54;
blue: r: -0.31, p = 0.39). Age was not significantly correlated with the peak pupil size and sus-
tained response.
Wrist actigraphy and sleep-wake activity
A subset of 12 participants, 5 controls and 7 pre-AD participants completed the wrist actigra-
phy recording. Compared with controls, pre-AD participants showed no statistically signifi-
cant difference in sleep efficiency (Fig 3A, Table 3). Measurements of most 10 average (M10)
for the wake period, and least 5 average (L5) for the night period were slightly decreased
Table 1. Demographic data of pre-AD disease participants and controls.
Control Pre-AD P value
Demographics
Participants (n) 10 10
Female, % 70 90
Age, yrs 72.7 ± 7.9 75.7 ± 6.3 0.65
Body Mass Index 28.5 ± 6.5 26.2 ± 2.9 0.62
Visual Acuity, log MAR 0.0 ± 0.0 0.1 ± 0.1 0.99
Aβ42 /Tau ratio 4.3 ± 1.2 1.5 ± 0.4 0.0007
Mean ± standard deviation.
P-values were calculated using the non-parametric Mann-Whitney U Test.
Statistical significance was defined as P values < 0.05.
Pre-AD, pre-symptomatic Alzheimer’s disease.
https://doi.org/10.1371/journal.pone.0226197.t001
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compared with controls (Table 3). However, these results were not statistically significant.
Additional actigraphy measurements of sleep time in hours, relative amplitude (RA), intra-
daily variability (IV), and interdaily stability (IS), showed no statistically significant difference
in pre-AD participants compared with controls (Fig 3B, Table 3). In the control group, there
was no significant correlation between Aß42/Tau ratios for sleep parameters (actual sleep time,
sleep efficiency, RA, IV, and IS). For the pre-AD group, there was a significant relationship
between pathologic CSF marker ratios and IV, with greater Aß42/Tau ratios correlating with
increased IV (r2: 0.88, p = 0.02). No other actigraphy markers were significantly correlated
with Aß42/Tau ratios in the pre-AD group.
Fig 1. Normalized pupillary light response (PLR) following photopically matched red (620 nm) and blue stimuli (450nm) at 250 or 2.3 log cd/m2. (A)
Following the red stimulus, individual normalized PLRs of pre-AD individuals (n = 10, dashed red) and the average pre-AD PLR (solid red). (B) Individual
normalized PLRs in controls (n = 10, dashed red) and the average control PLR (solid red). (C) Following the blue stimulus, individual normalized PLRs of pre-AD
individuals (n = 10, dashed blue) and average pre-AD PLR (solid blue). (D) Individual controls (n = 9, dashed blue) and the average control PLR (solid blue). Pre-AD,
pre-symptomatic Alzheimer’s disease.
https://doi.org/10.1371/journal.pone.0226197.g001
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In the pre-AD participants, actigraphy recordings showed variability with some partici-
pants resembling the pattern of controls (Fig 4A and 4B) and others with greater disruptions
in rest-activity rhythms (Fig 4C). This pre-AD example (Fig 4C) spent less total sleep time
with greater intra-daily variability and lower interdaily stability compared to the control exam-
ple (Fig 4A) as well as the pre-AD participant that resembled the control (Fig 4B).
Measurements of subjective sleep
All 20 participants completed all three sleep questionnaires. 4 participants (2 controls, 2 pre-
AD) had pathologic ESS scores and 8 participants (5 controls, 3 pre-AD) had pathologic PSQI
scores. None of the participants scored high risk for sleep apnea as evaluated by the Berlin
Questionnaire. Three participants (1 control, 2 pre-AD) were either previously diagnosed with
obstructive sleep apnea or were on treatment at the time of the study and were excluded from
the analysis. One control participant was excluded based on their elevated PSQI score of 19
and ESS scores of 15.
We compared subjective sleep scores in a total of 16 participants, 8 controls and 8 pre-AD
participants. Compared with controls, pre-AD participants did not report significantly differ-
ent subjective scores of sleep as evaluated by all three sleep questionnaires (Table 3). There was
also no statistically significant correlation between Aβ42 /Tau ratios and subjective sleep scores
in all participants.
Discussion
Melanopsin RGCs are affected in AD, but the functional impact of their loss is not well charac-
terized. Our results measuring the function of mRGCs with chromatic pupillometry and rest-
Fig 2. Pupillometry measurements in pre-AD and controls. Box whisker plots are shown comparing the pupillary light response following the red (620
nm) and blue stimulus (450 nm) for controls (black) and pre-AD participants (green). (A) Normalized peak pupil size and (B) normalized sustained pupil
response as a change from baseline pupil size. Peak pupil size was defined as normalized pupil size at point of maximum pupil constriction or minimum pupil
size. Sustained response was defined as the median normalized pupil size in the time window between 6 to 8 seconds from flash onset. Pre-AD, pre-
symptomatic Alzheimer’s disease.
https://doi.org/10.1371/journal.pone.0226197.g002
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activity circadian rhythm with actigraphy did not demonstrate statistically significant differ-
ences in the pupil response to colored stimuli and in quantitative sleep and circadian markers
assessed by wrist actigraphy in pre-AD participants compared with controls. However, in the
pre-AD cohort there is a higher variability in melanopsin function as evaluated by PLR to the
blue stimulus. In addition, the variability of actigraphy results in pre-AD compared to controls
also suggest potential changes in melanopsin function even in the very early stages of the
pathology, before symptoms become apparent.
When assessing changes in melanopsin RGCs in disease states, identifying mRGC subtypes
is important for understanding mRGC functions since each subtype likely has different non-
imaging forming functions in the eye, including photo-synchronization of our circadian
rhythm, sleep-wake cycle, pupillary light response, and cognition [32–35]. Six mRGC subtypes
(M1 to M6) have been described in rodents [14, 36, 37]. In human retinas, Hannibal and coau-
thors identified six (M1, displaced M1, gigantic M1, gigantic displaced M1, M2, M4) mRGC
subtypes [38]. The different subtypes are unevenly distributed in the human retinas, suggesting
different roles and functions but their functions are not clearly elucidated [38]. One human
study showed the projections of mRGCs to the to the suprachiasmatic nucleus (SCN), the cen-
ter of our circadian clock [15], and one study demonstrated retinal projections to the SCN, the
lateral geniculate complex including the pre-geniculate nucleus, the pretectal olivary nucleus,
the nucleus of the optic tract, the brachium of the superior colliculus, and the superior collicu-
lus in the macaque monkeys [39]. Post-mortem studies in aging populations above age 70
showed statistically significant age-dependent decrease in mRGC subtypes M1d and M3 cells,
and trending changes in other mRGC subtypes [35, 40]. In one study in Parkinson’s disease by
Table 2. Chromatic pupillometry data for controls and pre-AD.
Control Pre-AD P value
Red (620nm)
Participants 10 10
Baseline Pupil Size 5.66 ± 1.1 4.81 ± 1.54 0.35
(3.94–7.05) (2.38–6.82)
Peak Pupil Size 0.52 ± 0.07 0.54 ± 0.07 0.63
(0.40–0.64) (0.46–0.70)
Sustained Response 0.89 ± 0.07 0.89 ± 0.07 0.74
(0.77–0.99) (0.83–1.03)
Blue (450nm)
Participants 9 10
Baseline Pupil Size 5.15 ± 1.07 4.62 ± 1.46 0.50
(3.94–6.89) (2.34–6.68)
Peak Pupil Size 0.45 ± 0.02 0.50 ± 0.12 0.55
(0.40–0.48) (0.35–0.71)
Sustained Response 0.57 ± 0.08 0.59 ± 0.11 0.50
(0.51–0.77) (0.39–0.80)
Mean ± standard deviation. Red (620nm) and blue stimulus (450 nm) presented at 250 cd/m2. Baseline pupil
size = average pupil size during the 1 second before stimulus onset. Peak pupil size = normalized pupil size at point of
maximum pupil constriction or minimum pupil size. Sustained response = normalized median pupil size in the time
window between 6 to 8 seconds from flash onset. Statistical significance was defined as P values < 0.05. Pre-AD: Pre-
symptomatic Alzheimer’s disease.
https://doi.org/10.1371/journal.pone.0226197.t002
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Ortuño-Lizara´n and colleagues, the M1d was the most affected mRGC subtype, showing a
decrease in M1d density as well as morphological changes [41, 42].
Melanopsin subtypes in Alzheimer’s retinas have not yet been characterized, and it is diffi-
cult to drive from chromatic pupillometry an inference on the specific subtype responsible of
the phenotype without histological post-mortem data. Thus, the possible effect of pre-symp-
tomatic AD on each mRGC subtype is unclear and yet to be explored. Based on our results
(impairment of both pupillometry and actigraphic measures) and since these two functions
are provided by different mRGC subtypes we cannot specifically identify which mRGC sub-
type is affected in pre-AD. Future post-mortem studies are needed to address this specific
question.
A few pupillometry studies are available in AD and pre-AD using variable methods, flash
intensities, and pupillometry measurements, and not specifically addressing the mRGC contri-
bution [24–26]. One study used white flash stimuli in AD patients and noted characteristic
changes in the maximum constriction velocity and maximum constriction acceleration [24].
Similarly, Frost and coauthors demonstrated similar significant changes in PLR in AD with an
increase in latency and amount in PLR (constriction velocity and amplitude), and a more
rapid return to baseline pupil size after offset compared to controls [26]. Van Stavern and
coauthors measured the PLR following white light stimulus (949nm) in pre-AD individuals
and found no significant differences in pupillometry evaluation compared with controls [25].
Chromatic pupillometry, with protocols focusing on the melanopsin condition with photo-
pically matched intense blue and red stimuli, is thought to specifically measure mRGC func-
tion [20, 21]. By comparing the difference in responses to the red and blue stimuli, the
Fig 3. Wrist actigraphy measurements in pre-AD and controls. Box whisker plots of (A) Actual sleep (%) and Sleep efficiency (%), (B) Relative Amplitude
(RA), Interdaily Stability (IS), Intra-daily Variability (IV) for controls (black, n = 5) and pre-AD individuals (green, n = 7). Actual sleep (%) was calculated as
total sleep time in minutes divided by assumed sleep time (total elapsed time between ‘Fell Asleep’ and ‘Woke Up’ times). Sleep efficiency was calculated by the
percentage of total sleep time divided by time in bed. Pre-AD, pre-symptomatic Alzheimer’s disease.
https://doi.org/10.1371/journal.pone.0226197.g003
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melanopsin contribution can be isolated and measured. This has been successful in other
patient groups, including LHON and retinitis pigmentosa (RP) [20, 21]. In one LHON patient,
there was a significant delay in onset of mRGC-mediated PLR (blue stimulus) and no PLR to
the photopically matched red stimuli. In RP, there was preservation of mRGC function with a
sustained response to the blue stimulus that was larger than that of controls [20, 21]. In our
study, both pre-AD and control participants showed pupil constriction after intense red and
blue stimuli, suggesting preservation of cone and melanopsin function, respectively. The peak
amplitude following both the red and blue stimuli was no different between the two groups.
Although there was no statistically significant difference in the average PLR between the two
groups, we found an increased variability of PLRs following the blue stimulus in pre-AD com-
pared to controls, suggesting early changes in mRGC function. Overall, controls showed mini-
mal variability in the PLR to the blue stimulus (Fig 1D), except in one participant. PLR in this
participant showed a smaller sustained response compared to the average response. Interest-
ingly, this participant scored pathologic scores of subjective sleep on both PSQI and ESS. It is
possible, although without cognitive impairment, that changes in mRGC-driven PLR and rest-
activity circadian changes display early mRGC dysfunction, signaling a possible progression to
AD.
Comparing pupillometry results in pre-AD is challenging due to the different categoriza-
tions of pre-AD. In one study, pre-AD was labeled in healthy controls with high neocortical
amyloid burden, and compared to controls finding a significant difference in maximum con-
striction velocity [26]. Van Stavern and coauthors classified pre-AD based on having one or
both of the following biomarkers: pathologic CSF Aß42 levels and abnormal mean cortical
binding potential of Aß as measured on positron emission tomography (PET) [25]. Even using
a different methodology and patient population, we did not find significant differences in
Table 3. Wrist actigraphy and sleep quality data.
Control Pre-AD P value
Actigraphy
Participants 5 7
Sleep Time, hr 6.4 ± 1.3 6.7 ± 1.7 0.99
Efficiency, % 81.2 ± 7.6 85.1 ± 5.6 0.27
Relative Amplitude 0.75 ± 0.2 0.86 ± 0.1 0.34
Intra-daily Variability 0.83 ± 0.3 0.86 ± 0.2 0.76
Interdaily Stability 0.51 ± 0.2 0.59 ± 0.2 0.27
Fragmentation Index 28.6 ±14.3 31.5 ±14.0 0.99
M10 11673 ± 6563 10724 ± 3290 0.88
L5 1410 ± 854 753 ± 587 0.20
Sleep Questionnaires
Participants 8 8
Epworth 5.9 ± 4.1 4.1 ± 4.2 0.37
Berlin Low, Berlin High, % 75, 25 86, 14 0.99
PSQI 6.1 ± 2.1 6.1 ± 3.9 0.80
Quality of sleep from PSQI 3.6 ± 4.9 5.1 ± 6.8 0.73
Mean ± standard deviation.
Statistical significance was set at P value < 0.05.
Pre-AD, pre-symptomatic Alzheimer’s disease. M10, Most 10 Average; L5, Least 5 Average; PSQI, Pittsburgh Sleep Quality Index.
https://doi.org/10.1371/journal.pone.0226197.t003
Melanopsin function and sleep-wake activity in pre-symptomatic Alzheimer’s
PLOS ONE | https://doi.org/10.1371/journal.pone.0226197 December 10, 2019 11 / 17
Melanopsin function and sleep-wake activity in pre-symptomatic Alzheimer’s
PLOS ONE | https://doi.org/10.1371/journal.pone.0226197 December 10, 2019 12 / 17
quantitative measurements of PLR. We did, however, note an increased variability of PLR in
the pre-AD group relative to controls, particularly with the intense blue stimulus.
Sleep-wake disturbances affect up to 40% of AD patients, impacting their quality of life, and
disrupting their circadian rhythms [17, 35, 43]. Actigraphy recordings in AD patients have
shown a significant decrease in sleep efficiency along with decreased activity during the day
and increased activity at night, as measured on actigraphy [8]. In our study, assessment of cir-
cadian rhythm and rest-activity patterns in pre-AD failed to demonstrate significant differ-
ences compared to controls. There were no significant early changes in sleep efficiency in AD
patients (75% in AD vs 90% in controls) [8]. Since the severity of dementia is positively corre-
lated to the severity of circadian dysfunction, our results may be explained by the absence of
cognitive dysfunction in our cohort, [16]. In another study, AD patients with poor stability of
circadian parameters had the poorest prognosis, suggesting circadian dysfunction and irregu-
lar sleep-wake activity can predict cognitive outcome [44]. However, longitudinal studies have
shown that actigraphy in AD does not worsen over one year, despite significant cognitive
decline [44]. Further studies are needed to assess the presence and evolution of sleep distur-
bances in AD.
We also found a slight decrease in the average L5 and M10 actigraphy measurements in the
pre-AD group, indicating a less restful or inactive period and less active and regular wake
period, respectively. There was also a slight increase in intra-daily variability (IV) in pre-AD,
and a significant positive correlation between IV and Aβ42 /Tau ratios in the CSF. This latter
relationship may reflect a smaller total Tau level in the pre-AD participants in this early pathol-
ogy stage. We also observed a higher variability in the circadian rhythm of the pre-AD group
with some participants resembling the rhythm of controls, while others displayed irregularities
in the rest-wake activity pattern. These results provide evidence of early changes in the circa-
dian rhythm in pre-AD participants, also seen in another study, showing significantly worse
sleep efficiency without changes in total sleep time in pre-AD [17]. In agreement with our
quantitative findings, assessment of subjective sleep in our pre-AD group also showed no sig-
nificant changes, similar to a report using the sleep questionnaires in AD patients [8]. Overall,
sleep disturbances are also difficult to assess prior to cognitive changes, and larger samples and
longitudinal studies are needed to further assess early changes in circadian dysfunction.
The major limitation of this study is the small sample size and cross-sectional nature of the
study. We were also unable to follow the exact referenced protocol of wavelength and lumi-
nance to measure the melanopsin response with the blue stimuli. Park and coauthors assessed
their melanopsin-mediated PLR using 470nm at a luminance of 450 cd/m2 (2.5 log cd/m2)
while we used(450nm at 250 cd/m2 or 2.3 log cd/m2) [21]. Melanopsin-driven PLR is typically
triggered at a luminance of 30 to 100 cd/m2 (0.5–1 log cd/m2), suggesting that our hardware
was capable of sufficiently driving the PLR. In addition, we were unable to assess rest-activity
circadian rhythm for all participants who completed pupillometry given the limited number of
wrist actigraphy devices.
Conclusions
The variability in the melanopsin driven light pupil response and in circadian rest-activity
measures in our pre-AD cohort may suggest the presence of early mRGC pathology. Larger
Fig 4. Individual wrist actigraphy examples. Actigraphy results in (A) a control example in black and (B) an example of pre-AD
participants with an actigraphy profile similar to controls, and (C) another pre-AD participant who recorded greater irregularities
in circadian rhythm and interruptions during sleep-wake activity in green, including a decrease in sleep time, lower sleep efficiency,
greater intra-daily variability, and lower interdaily stability. Y-axis represents counts per epoch. Pre-AD, pre-symptomatic
Alzheimer’s disease.
https://doi.org/10.1371/journal.pone.0226197.g004
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and prospective studies are needed to further evaluate the role of objective chromatic pupillo-
metry and circadian measurements as potential in vivo biomarkers for measuring melanopsin
function. This can help clarify how melanopsin function is affected in the neuro-degeneration
of AD pathology prior to cognitive changes.
Author Contributions
Conceptualization: Angela J. Oh, Giulia Amore, William Sultan, Samuel Asanad, Chiara La
Morgia, Rustum Karanjia, Michael G. Harrington, Alfredo A. Sadun.
Data curation: Angela J. Oh, Giulia Amore, William Sultan, Chiara La Morgia, Rustum Kar-
anjia, Michael G. Harrington, Alfredo A. Sadun.
Formal analysis: Angela J. Oh, Giulia Amore, William Sultan, Jason C. Park, Rustum Karan-
jia, Michael G. Harrington, Alfredo A. Sadun.
Funding acquisition: Angela J. Oh, Samuel Asanad, Chiara La Morgia, Rustum Karanjia,
Michael G. Harrington, Alfredo A. Sadun.
Investigation: Angela J. Oh, Giulia Amore, Chiara La Morgia, Rustum Karanjia, Michael G.
Harrington, Alfredo A. Sadun.
Methodology: Angela J. Oh, Giulia Amore, Samuel Asanad, Jason C. Park, Martina Romag-
noli, Chiara La Morgia, Rustum Karanjia, Michael G. Harrington, Alfredo A. Sadun.
Project administration: Angela J. Oh, Giulia Amore, Samuel Asanad, Chiara La Morgia, Rus-
tum Karanjia, Michael G. Harrington, Alfredo A. Sadun.
Resources: Angela J. Oh, Giulia Amore, Samuel Asanad, Jason C. Park, Martina Romagnoli,
Chiara La Morgia, Rustum Karanjia, Michael G. Harrington, Alfredo A. Sadun.
Software: Angela J. Oh, Giulia Amore, Jason C. Park, Martina Romagnoli, Chiara La Morgia,
Rustum Karanjia, Michael G. Harrington, Alfredo A. Sadun.
Supervision: Angela J. Oh, Giulia Amore, Chiara La Morgia, Rustum Karanjia, Michael G.
Harrington, Alfredo A. Sadun.
Validation: Angela J. Oh, Giulia Amore, Jason C. Park, Chiara La Morgia, Rustum Karanjia,
Michael G. Harrington, Alfredo A. Sadun.
Visualization: Angela J. Oh, Giulia Amore, Chiara La Morgia, Rustum Karanjia, Michael G.
Harrington, Alfredo A. Sadun.
Writing – original draft: Angela J. Oh, Giulia Amore.
Writing – review & editing: Angela J. Oh, Giulia Amore, William Sultan, Samuel Asanad,
Jason C. Park, Martina Romagnoli, Chiara La Morgia, Rustum Karanjia, Michael G. Har-
rington, Alfredo A. Sadun.
References
1. Koronyo Y, Biggs D, Barron E, Boyer DS, Pearlman JA, Au WJ, et al. Retinal amyloid pathology and
proof-of-concept imaging trial in Alzheimer’s disease. JCI Insight. 2017; 2(16). Epub 2017/08/18.
https://doi.org/10.1172/jci.insight.93621 PMID: 28814675; PubMed Central PMCID: PMC5621887.
2. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, et al. Identification of amy-
loid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal pla-
ques in a mouse model. Neuroimage. 2011; 54 Suppl 1:S204–17. Epub 2010/06/17. https://doi.org/10.
1016/j.neuroimage.2010.06.020 PMID: 20550967; PubMed Central PMCID: PMC2991559.
Melanopsin function and sleep-wake activity in pre-symptomatic Alzheimer’s
PLOS ONE | https://doi.org/10.1371/journal.pone.0226197 December 10, 2019 14 / 17
3. Hart NJ, Koronyo Y, Black KL, Koronyo-Hamaoui M. Ocular indicators of Alzheimer’s: exploring disease
in the retina. Acta Neuropathol. 2016; 132(6):767–87. Epub 2016/09/21. https://doi.org/10.1007/
s00401-016-1613-6 PMID: 27645291; PubMed Central PMCID: PMC5106496.
4. Harrington MG, Chiang J, Pogoda JM, Gomez M, Thomas K, Marion SD, et al. Executive function
changes before memory in preclinical Alzheimer’s pathology: a prospective, cross-sectional, case con-
trol study. PLoS One. 2013; 8(11):e79378. Epub 2013/11/22. https://doi.org/10.1371/journal.pone.
0079378 PMID: 24260210; PubMed Central PMCID: PMC3832547.
5. Sadun AA, Asanad S. The Eye in Alzheimer’s Disease. Ophthalmology. 2019; 126(4):511–2. Epub
2019/03/27. https://doi.org/10.1016/j.ophtha.2018.10.001 PMID: 30910035.
6. Lim JK, Li QX, He Z, Vingrys AJ, Wong VH, Currier N, et al. The Eye As a Biomarker for Alzheimer’s
Disease. Front Neurosci. 2016; 10:536. Epub 2016/12/03. https://doi.org/10.3389/fnins.2016.00536
PMID: 27909396; PubMed Central PMCID: PMC5112261.
7. Asanad S, Ross-Cisneros FN, Nassisi M, Barron E, Karanjia R, Sadun AA. The Retina in Alzheimer’s
Disease: Histomorphometric Analysis of an Ophthalmologic Biomarker. Invest Ophthalmol Vis Sci.
2019; 60(5):1491–500. Epub 2019/04/12. https://doi.org/10.1167/iovs.18-25966 PMID: 30973577.
8. La Morgia C, Ross-Cisneros FN, Koronyo Y, Hannibal J, Gallassi R, Cantalupo G, et al. Melanopsin reti-
nal ganglion cell loss in Alzheimer disease. Ann Neurol. 2016; 79(1):90–109. Epub 2015/10/28. https://
doi.org/10.1002/ana.24548 PMID: 26505992; PubMed Central PMCID: PMC4737313.
9. La Morgia C, Ross-Cisneros FN, Sadun AA, Carelli V. Retinal Ganglion Cells and Circadian Rhythms in
Alzheimer’s Disease, Parkinson’s Disease, and Beyond. Front Neurol. 2017; 8:162. Epub 2017/05/20.
https://doi.org/10.3389/fneur.2017.00162 PMID: 28522986; PubMed Central PMCID: PMC5415575.
10. Coppola G, Di Renzo A, Ziccardi L, Martelli F, Fadda A, Manni G, et al. Optical Coherence Tomography
in Alzheimer’s Disease: A Meta-Analysis. PLoS One. 2015; 10(8):e0134750. Epub 2015/08/08. https://
doi.org/10.1371/journal.pone.0134750 PMID: 26252902; PubMed Central PMCID: PMC4529274.
11. den Haan J, Verbraak FD, Visser PJ, Bouwman FH. Retinal thickness in Alzheimer’s disease: A sys-
tematic review and meta-analysis. Alzheimers Dement (Amst). 2017; 6:162–70. Epub 2017/03/10.
https://doi.org/10.1016/j.dadm.2016.12.014 PMID: 28275698; PubMed Central PMCID: PMC5328759.
12. Asanad S, Tian JJ, Frousiakis S, Jiang JP, Kogachi K, Felix CM, et al. Optical Coherence Tomography
of the Retinal Ganglion Cell Complex in Leber’s Hereditary Optic Neuropathy and Dominant Optic Atro-
phy. Curr Eye Res. 2019; 44(6):638–44. Epub 2019/01/17. https://doi.org/10.1080/02713683.2019.
1567792 PMID: 30649972.
13. Tales A, Troscianko T, Lush D, Haworth J, Wilcock GK, Butler SR. The pupillary light reflex in aging and
Alzheimer’s disease. Aging (Milano). 2001; 13(6):473–8. Epub 2002/02/16. PMID: 11845975.
14. Schmidt TM, Chen SK, Hattar S. Intrinsically photosensitive retinal ganglion cells: many subtypes,
diverse functions. Trends Neurosci. 2011; 34(11):572–80. Epub 2011/08/06. https://doi.org/10.1016/j.
tins.2011.07.001 PMID: 21816493; PubMed Central PMCID: PMC3200463.
15. Hannibal J, Hindersson P, Ostergaard J, Georg B, Heegaard S, Larsen PJ, et al. Melanopsin is
expressed in PACAP-containing retinal ganglion cells of the human retinohypothalamic tract. Invest
Ophthalmol Vis Sci. 2004; 45(11):4202–9. Epub 2004/10/27. https://doi.org/10.1167/iovs.04-0313
PMID: 15505076.
16. Feng R, Li L, Yu H, Liu M, Zhao W. Melanopsin retinal ganglion cell loss and circadian dysfunction in
Alzheimer’s disease (Review). Mol Med Rep. 2016; 13(4):3397–400. Epub 2016/03/05. https://doi.org/
10.3892/mmr.2016.4966 PMID: 26935586; PubMed Central PMCID: PMC4805057.
17. Ju YE, McLeland JS, Toedebusch CD, Xiong C, Fagan AM, Duntley SP, et al. Sleep quality and preclini-
cal Alzheimer disease. JAMA Neurol. 2013; 70(5):587–93. Epub 2013/03/13. https://doi.org/10.1001/
jamaneurol.2013.2334 PMID: 23479184; PubMed Central PMCID: PMC3676720.
18. Peter-Derex L, Yammine P, Bastuji H, Croisile B. Sleep and Alzheimer’s disease. Sleep Med Rev.
2015; 19:29–38. Epub 2014/05/23. https://doi.org/10.1016/j.smrv.2014.03.007 PMID: 24846773.
19. La Morgia C, Carelli V, Carbonelli M. Melanopsin Retinal Ganglion Cells and Pupil: Clinical Implications
for Neuro-Ophthalmology. Front Neurol. 2018; 9:1047. Epub 2018/12/26. https://doi.org/10.3389/fneur.
2018.01047 PMID: 30581410; PubMed Central PMCID: PMC6292931.
20. Moura AL, Nagy BV, La Morgia C, Barboni P, Oliveira AG, Salomao SR, et al. The pupil light reflex in
Leber’s hereditary optic neuropathy: evidence for preservation of melanopsin-expressing retinal gan-
glion cells. Invest Ophthalmol Vis Sci. 2013; 54(7):4471–7. Epub 2013/06/06. https://doi.org/10.1167/
iovs.12-11137 PMID: 23737476; PubMed Central PMCID: PMC4322722.
21. Park JC, Moura AL, Raza AS, Rhee DW, Kardon RH, Hood DC. Toward a clinical protocol for assessing
rod, cone, and melanopsin contributions to the human pupil response. Invest Ophthalmol Vis Sci. 2011;
52(9):6624–35. Epub 2011/07/12. https://doi.org/10.1167/iovs.11-7586 PMID: 21743008; PubMed
Central PMCID: PMC3175993.
Melanopsin function and sleep-wake activity in pre-symptomatic Alzheimer’s
PLOS ONE | https://doi.org/10.1371/journal.pone.0226197 December 10, 2019 15 / 17
22. Kardon R, Anderson SC, Damarjian TG, Grace EM, Stone E, Kawasaki A. Chromatic pupil responses:
preferential activation of the melanopsin-mediated versus outer photoreceptor-mediated pupil light
reflex. Ophthalmology. 2009; 116(8):1564–73. Epub 2009/06/09. https://doi.org/10.1016/j.ophtha.2009.
02.007 PMID: 19501408.
23. La Morgia C, Ross-Cisneros FN, Hannibal J, Montagna P, Sadun AA, Carelli V. Melanopsin-expressing
retinal ganglion cells: implications for human diseases. Vision Res. 2011; 51(2):296–302. Epub 2010/
08/10. https://doi.org/10.1016/j.visres.2010.07.023 PMID: 20691201.
24. Chougule PS, Najjar RP, Finkelstein MT, Kandiah N, Milea D. Light-Induced Pupillary Responses in
Alzheimer’s Disease. Front Neurol. 2019; 10:360. Epub 2019/04/30. https://doi.org/10.3389/fneur.
2019.00360 PMID: 31031692; PubMed Central PMCID: PMC6473037.
25. Van Stavern GP, Bei L, Shui YB, Huecker J, Gordon M. Pupillary light reaction in preclinical Alzheimer’s
disease subjects compared with normal ageing controls. Br J Ophthalmol. 2019; 103(7):971–5. Epub
2018/09/13. https://doi.org/10.1136/bjophthalmol-2018-312425 PMID: 30206156.
26. Frost S, Robinson L, Rowe CC, Ames D, Masters CL, Taddei K, et al. Evaluation of Cholinergic Defi-
ciency in Preclinical Alzheimer’s Disease Using Pupillometry. J Ophthalmol. 2017; 2017:7935406.
Epub 2017/09/13. https://doi.org/10.1155/2017/7935406 PMID: 28894607; PubMed Central PMCID:
PMC5574262.
27. Fotiou D, Kaltsatou A, Tsiptsios D, Nakou M. Evaluation of the cholinergic hypothesis in Alzheimer’s dis-
ease with neuropsychological methods. Aging Clin Exp Res. 2015; 27(5):727–33. Epub 2015/03/10.
https://doi.org/10.1007/s40520-015-0321-8 PMID: 25749905.
28. Rukmini AV, Milea D, Gooley JJ. Chromatic Pupillometry Methods for Assessing Photoreceptor Health
in Retinal and Optic Nerve Diseases. Front Neurol. 2019; 10:76. Epub 2019/02/28. https://doi.org/10.
3389/fneur.2019.00076 PMID: 30809186; PubMed Central PMCID: PMC6379484.
29. Besser L, Kukull W, Knopman DS, Chui H, Galasko D, Weintraub S, et al. Version 3 of the National Alz-
heimer’s Coordinating Center’s Uniform Data Set. Alzheimer Dis Assoc Disord. 2018; 32(4):351–8.
Epub 2018/10/31. https://doi.org/10.1097/WAD.0000000000000279 PMID: 30376508; PubMed Cen-
tral PMCID: PMC6249084.
30. Witting W, Kwa IH, Eikelenboom P, Mirmiran M, Swaab DF. Alterations in the circadian rest-activity
rhythm in aging and Alzheimer’s disease. Biol Psychiatry. 1990; 27(6):563–72. Epub 1990/03/15.
https://doi.org/10.1016/0006-3223(90)90523-5 PMID: 2322616.
31. Lei S, Goltz HC, Chandrakumar M, Wong AM. Full-field chromatic pupillometry for the assessment of
the postillumination pupil response driven by melanopsin-containing retinal ganglion cells. Invest
Ophthalmol Vis Sci. 2014; 55(7):4496–503. Epub 2014/06/14. https://doi.org/10.1167/iovs.14-14103
PMID: 24925879.
32. Li JY, Schmidt TM. Divergent projection patterns of M1 ipRGC subtypes. J Comp Neurol. 2018; 526
(13):2010–8. Epub 2018/06/12. https://doi.org/10.1002/cne.24469 PMID: 29888785; PubMed Central
PMCID: PMC6158116.
33. Baver SB, Pickard GE, Sollars PJ, Pickard GE. Two types of melanopsin retinal ganglion cell differen-
tially innervate the hypothalamic suprachiasmatic nucleus and the olivary pretectal nucleus. Eur J Neu-
rosci. 2008; 27(7):1763–70. Epub 2008/03/29. https://doi.org/10.1111/j.1460-9568.2008.06149.x
PMID: 18371076.
34. Chen SK, Badea TC, Hattar S. Photoentrainment and pupillary light reflex are mediated by distinct pop-
ulations of ipRGCs. Nature. 2011; 476(7358):92–5. Epub 2011/07/19. https://doi.org/10.1038/
nature10206 PMID: 21765429; PubMed Central PMCID: PMC3150726.
35. Esquiva G, Hannibal J. Melanopsin-expressing retinal ganglion cells in aging and disease. Histol Histo-
pathol. 2019:18138. Epub 2019/06/21. https://doi.org/10.14670/HH-18-138 PMID: 31219170.
36. Reifler AN, Chervenak AP, Dolikian ME, Benenati BA, Meyers BS, Demertzis ZD, et al. The rat retina
has five types of ganglion-cell photoreceptors. Exp Eye Res. 2015; 130:17–28. Epub 2014/12/03.
https://doi.org/10.1016/j.exer.2014.11.010 PMID: 25450063; PubMed Central PMCID: PMC4276437.
37. Quattrochi LE, Stabio ME, Kim I, Ilardi MC, Michelle Fogerson P, Leyrer ML, et al. The M6 cell: A small-
field bistratified photosensitive retinal ganglion cell. J Comp Neurol. 2019; 527(1):297–311. Epub 2018/
10/13. https://doi.org/10.1002/cne.24556 PMID: 30311650; PubMed Central PMCID: PMC6594700.
38. Hannibal J, Christiansen AT, Heegaard S, Fahrenkrug J, Kiilgaard JF. Melanopsin expressing human
retinal ganglion cells: Subtypes, distribution, and intraretinal connectivity. J Comp Neurol. 2017; 525
(8):1934–61. Epub 2017/02/06. https://doi.org/10.1002/cne.24181 PMID: 28160289.
39. Hannibal J, Kankipati L, Strang CE, Peterson BB, Dacey D, Gamlin PD. Central projections of intrinsi-
cally photosensitive retinal ganglion cells in the macaque monkey. J Comp Neurol. 2014; 522
(10):2231–48. Epub 2014/04/23. https://doi.org/10.1002/cne.23588 PMID: 24752373; PubMed Central
PMCID: PMC3996456.
Melanopsin function and sleep-wake activity in pre-symptomatic Alzheimer’s
PLOS ONE | https://doi.org/10.1371/journal.pone.0226197 December 10, 2019 16 / 17
40. Esquiva G, Lax P, Perez-Santonja JJ, Garcia-Fernandez JM, Cuenca N. Loss of Melanopsin-Express-
ing Ganglion Cell Subtypes and Dendritic Degeneration in the Aging Human Retina. Front Aging Neu-
rosci. 2017; 9:79. Epub 2017/04/20. https://doi.org/10.3389/fnagi.2017.00079 PMID: 28420980;
PubMed Central PMCID: PMC5378720.
41. Lax P, Ortuno-Lizaran I, Maneu V, Vidal-Sanz M, Cuenca N. Photosensitive Melanopsin-Containing
Retinal Ganglion Cells in Health and Disease: Implications for Circadian Rhythms. Int J Mol Sci. 2019;
20(13). Epub 2019/07/03. https://doi.org/10.3390/ijms20133164 PMID: 31261700.
42. Ortuno-Lizaran I, Esquiva G, Beach TG, Serrano GE, Adler CH, Lax P, et al. Degeneration of human
photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson’s
disease. Acta Neuropathol Commun. 2018; 6(1):90. Epub 2018/09/12. https://doi.org/10.1186/s40478-
018-0596-z PMID: 30201049; PubMed Central PMCID: PMC6130068.
43. Camargos EF, Pandolfi MB, Dias MP, Quintas JL, Guimaraes RM, Nobrega Ode T. Incidence of sleep
disorders in patients with Alzheimer disease. Einstein (Sao Paulo). 2011; 9(4):461–5. Epub 2011/12/01.
https://doi.org/10.1590/S1679-45082011AO2145 PMID: 26761246.
44. Hatfield CF, Herbert J, van Someren EJ, Hodges JR, Hastings MH. Disrupted daily activity/rest cycles
in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer’s dementia. Brain.
2004; 127(Pt 5):1061–74. Epub 2004/03/05. https://doi.org/10.1093/brain/awh129 PMID: 14998915.
Melanopsin function and sleep-wake activity in pre-symptomatic Alzheimer’s
PLOS ONE | https://doi.org/10.1371/journal.pone.0226197 December 10, 2019 17 / 17
